Navigation Links
FDA approves MyocondaR IND for MAP in Crohn's Disease

at which will now be an all-in-one oral capsule, the increased dosages and the new indication being sought.

"We are very pleased to have reached this key milestone in the development of MyocondaR. There is clearly a need for this type of therapy for the substantial subset of Crohn's Disease patients infected with MAP who are not well served by current therapies," said Patrick McLean, CEO of Giaconda "Giaconda is now another step closer to achieving its aim of bringing this product to market as soon as possible for the benefit of patients who are infected with MAP.

The development of MyocondaR is supported by a significant number of opinion leaders in the field". About Giaconda Limited Giaconda Limited is a biotechnology company involved in developing and licensing innovative and cost effective medical therapies in the field of gastroenterology. Giaconda's products are targeted towards the treatment of serious conditions that are not adequately addressed by any existing therapy. In this way, Giaconda's products are intended to satisfy these significant unmet medical needs of the gastrointestinal market. The Giaconda portfolio consists of five products, all of which are novel combinations of known compounds. Giaconda has two lead products, MyocondaR for the treatment of Crohn's Disease and HelicondaR for the treatment of resistant Helicobacter pylori infection. For more information please visit www.giacondalimited.com

About MyocondaR -
A Combination Antibiotic Therapy for the Treatment of Crohn's Disease MyocondaR, the Company's Anti-MAP therapy for the treatment of Crohn's Disease is a combination of three registered anti-mycobacterial drugs - rifabutin, clarithromycin and clofazimine. These three drugs are widely marketed world-wide for the treatment of mycobacterial and other infections. MyocondaR presents these three compounds in a specific patented combin
'"/>




Page: 1 2 3 4

Related medicine technology :

1. FDA approves IND on Lead Product M6G
2. ChemoCentryx Presents Positive Phase 2 Clinical Data for Traficet-EN in Crohns Disease at the Digestive Disease Week 2007 Conference
3. Enzo Biochem Individualized Oral Immune Regulation Therapy May Be Effective Approach to Treating Crohns Disease
4. UCB Presents Long-Term CImzia Data in Crohns Disease
5. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
6. Appendicitis: Evolving Tools to Diagnose a Classic Disease
7. Non-Invasive Diagnostic Tests for Celiac Disease
8. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Samaritans Alzheimers Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimers Disease
11. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA approves MyocondaR IND for MAP Crohn Disease
(Date:7/31/2014)... July 31, 2014  According to data released today ... 2015 average monthly Medicare Part D premium is expected ... than was originally projected, the Pharmaceutical Care Management Association ... continues to be a bright spot in American health ... each region and using cutting edge, cost-saving tools like ...
(Date:7/31/2014)... SAN DIEGO , July 31, 2014  Sorrento Therapeutics, ... death of Mr. Amar Singh , Chief Business Officer ... of apparent natural causes on July 30. "Sorrento ... dear friend and colleague. Our immediate thoughts go to Amar,s ... President and Chief Executive Officer. Mr. Singh ...
(Date:7/31/2014)... -- STAAR Surgical Company (NASDAQ: STAA ) ... and delivery systems for the eye today reported revenue ... $20.0 million, a 10% increase over $18.2 million reported ... currency basis, revenues grew 11% during the second quarter ... The effect of foreign currency exchange reduced sales by ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31
... 7 ActivBiotics, Inc. today,announced the results ... effect of rifalazil in the treatment of ... The results demonstrated,that treatment for two months ... in a significant improvement in walking distance,claudication ...
... the American Heart Association Scientific Sessions ... 2007 ... Nabi,Biopharmaceuticals (Nasdaq: NABI ) today announced the successful completion,of ... innovative and proprietary investigational vaccine being,developed to treat nicotine addiction ...
Cached Medicine Technology:Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 2Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 2Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 4Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 5Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 6Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 7
(Date:7/31/2014)... 31, 2014 Hoping to attract new customers ... trust , NutriGold is ready to ship out free ... make taking advantage of this offer fast and easy: ... and Development at NutriGold, "We know that every time customers ... their most precious asset: their own health or the health ...
(Date:7/31/2014)... TN (PRWEB) July 31, 2014 In many ... are required for proper storage of necessary life saving drugs. ... staff. Unfortunately there is still a high number of ambulances ... an EMT who steals the narcotics and even replaces the ... relief receives none. As seen in the case in Baraboo, ...
(Date:7/31/2014)... Niche Profit Classroom, a method and guide ... to provide a blueprint for anyone who is interested in ... prompting an investigative review. , Learn more about ... about the success of the information in this course is ... have stayed effective even through all of the major search ...
(Date:7/31/2014)... United Theological Seminary is pleased to welcome ... and Peter J. Bellini. Both began their teaching duties ... a Director of Non-Degree Programs, Mark Abbott, who begins ... Donne, Assistant Professor of New Testament, received a Ph.D. ... Second Temple Judaism, and Greek courses. His research interests ...
(Date:7/31/2014)... Angeles, CA (PRWEB) July 31, 2014 US ... his practice will now be known as Parsa Mohebi Hair ... has helped hundreds of patients in Southern California and around ... Los Angeles, Beverly Hills and Orange County. These patients achieved ... including many surgical techniques that were perfected by Dr. Mohebi. ...
Breaking Medicine News(10 mins):Health News:NutriGold Launches Product Samples Page for its Supplements 2Health News:NutriGold Launches Product Samples Page for its Supplements 3Health News:New MedixSafe Alert - Ambulances Must Have A Medical Safe, Narcotics Cabinet, or Drug Locker 2Health News:Niche Profit Classroom: Review Exposes Adam Short’s Guide to Building Niche Websites 2Health News:Growing Seminary Welcomes New Faculty 2Health News:US Hair Restoration Becomes Parsa Mohebi Hair Restoration 2
... Today the International and American Associations for Dental Research ... remains the number one journal of 64 journal published in ... new 2009 Five-Year Scientific Impact Factor (SIF) rankings, published by ... the JDR,s Five-Year SIF increased from 3.966 to 4.195. ...
... , ... open to the public, Andy Thomas job seminars teach participants unique personal marketing strategies ... Minutes to a Better Career”; Career counselor Thomas is a former talk show host ... 60 unemployed in attendance, and a drawing will be held for Thomas providing free ...
... DocGreet.com is ... their time and streamline their patient communication, that the company has announced a money back ... ... sure that the services available to Doctors, Physicians and Health Care Providers will monetize their ...
... ... of the Enterprise Architecture Professional Practice Guide and a brochure on Enterprise Architecture as a ... (PRWEB) June ... ,These abstracts provide the enterprise architect,s contract with the public they serve and consist of ...
... colonoscopy is effective and cost-effective when targeted to ... Gastroenterology , the official journal of the ... surveillance colonoscopy could be excessively costly or even ... and utilized practice that has the potential to ...
... Institute (NHLBI), part of the National Institutes of Health, is ... efficacy of red blood cell transfusions vary depending on how ... supports the first large, multi-center, randomized clinical trial to compare ... blood cells that have been stored for shorter or longer ...
Cached Medicine News:Health News:JDR increases its 5-Year SIF and remains number one dental journal of 64 in its category 2Health News:Columbia Extreme Job Makeover Slated for June 26 2Health News:Columbia Extreme Job Makeover Slated for June 26 3Health News:DocGreet Guarantees More Time and Money to Doctors and Health Care Providers 2Health News:Enterprise Architecture -- Breaking Away From The Pack 2Health News:Surveillance colonoscopy should be targeted to high-risk patients 2Health News:NHLBI funds research to improve safety of red blood cell transfusions 2Health News:NHLBI funds research to improve safety of red blood cell transfusions 3Health News:NHLBI funds research to improve safety of red blood cell transfusions 4Health News:NHLBI funds research to improve safety of red blood cell transfusions 5Health News:NHLBI funds research to improve safety of red blood cell transfusions 6Health News:NHLBI funds research to improve safety of red blood cell transfusions 7
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: